@clare__turnbull @iamslambert @timfrayling @carolinefwright @TheLancet @annekeluc @HelenVFirth @GeneticBill @mgtmccartney @Wilkie_Lab @RobinLachmann @group_tomlinson @lucymedgen There are also increasing numbers of studies of PRS which show they are cost-e
Tying these polygenic score cost effectiveness studies in here as most have been published since the ICDA PRS Task Force paper. As one would expect from a one-time sub-£100 assay that can be applied to dozens of clinical pathways, PGS cost effectiveness i
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
Glad to see more research answering this question!
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/qx7go5ZtQ2 CRC: https://t.co/6i3OdGV3BL CVD: https://t.co/I2dmNhN1pb https://t.co/IIhOeyY8a9 T2D: https://t.co/rw2KX7SjRY
@russt_j @johnrich Not that I expect you to understand a word of it. https://t.co/3PkHiStfMY
RT @VickersBiostats: A microsimulation paper recommends transforming mammography, choosing who to screen based on a polygenic risk score. H…
RT @waq0r: "There are two clear conclusions. First modeling studies should have as suppl. material well-annotated statistical code to allow…
RT @VickersBiostats: A microsimulation paper recommends transforming mammography, choosing who to screen based on a polygenic risk score. H…
"There are two clear conclusions. First modeling studies should have as suppl. material well-annotated statistical code to allow independent replication. Unlike empirical studies, where code is used to analyze an experiment, in a modelling study, the code
RT @VickersBiostats: A microsimulation paper recommends transforming mammography, choosing who to screen based on a polygenic risk score. H…
RT @VickersBiostats: A microsimulation paper recommends transforming mammography, choosing who to screen based on a polygenic risk score. H…
RT @VickersBiostats: A microsimulation paper recommends transforming mammography, choosing who to screen based on a polygenic risk score. H…
A microsimulation paper recommends transforming mammography, choosing who to screen based on a polygenic risk score. Huge interest (Altmetric ~300). One minor problem: the results appear to be an artifact of erroneous code. See comments section of https://
@paulpharoah @HealthWatchUK @MichaelBaum11 @VPrasadMDMPH @deb_cohen @susan_bewley @TranspariMED @HelenRSalisbury @mgtmccartney @cecilejanssens @DrMJoyner Paul, your own 2018 @JAMAOnc article with @Norapashayan et al makes it v clear that not offering breas
Retweeted from Eric Topol: Why we should do mammography on the basis of risk, not on a mass, routine screening basis: less harm, less cost https://t.co/VBUx2wlSTD @JAMAOnc by @Norapashayan @paulpharoah and colleagues #indivmed https://t.co/T71QdRwhoo #medi
RT @JAMAOnc: Not offering #BreastCancer #screening to women at lower risk could improve the cost-effectiveness of the screening program, re…
@LaurentLantieri @MartinWinckler @AgnesB55897959 @SNJMG @agnesbuzyn @Institut_cancer @Formindep @_CancerRose @UFCquechoisir @pourunemeuf @FrancoisBeguin @sandrine_cabut @estellesaget @pascale_santi @VPplenarysesh Idem en Norvège, pas d'influence sur la mor
RT @Adele_Rica: Really interesting read @Liz_ORiordan @bccww @BCCare @breastcancernow https://t.co/sqM87mazeq
Really interesting read @Liz_ORiordan @bccww @BCCare @breastcancernow
Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening https://t.co/cAu1te6r4b
@Cheryl_Cruwys @Adele_Rica @DenseBreastInfo Personalized screening is the goal. But until we can accurately define who is at low risk, all women should have annual mammo starting at 40, and supplemental screening for higher risk. The UK study that tried pe
リスクの高い人へ集中的に乳癌のスクリーニングをすることは過剰診断を避け、コストが巨額になるのを防ぐ&質調整生存年を損なわず、死亡リスクの低下効果は保持される。Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer https://t.co/vTbOiGWLho
RT @JAMAOnc: Not offering #BreastCancer #screening to women at lower risk could improve the cost-effectiveness of the screening program, re…
Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening https://t.co/Ro3Zonq2Fe Personalized Screening!!
Not offering #BreastCancer #screening to women at lower risk could improve the cost-effectiveness of the screening program, reduce overdiagnosis, & maintain benefits of screening. https://t.co/asTw9ozZvt #BCSM #mammogram #mammography https://t.co/qUAN5
Très logiquement un #dépistage généralisé du #cancerdusein en fonction du risque (par paliers) serait plus économe en surdiagnostic et en dépenses, sans diminuer son efficacité, selon un modèle britannique. https://t.co/Zkfyk8QlnN
RT @dipi1_con: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified #Screening for #BreastCancer https://t.co/BgjCnoieVq @JAMAO…
RT @dipi1_con: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified #Screening for #BreastCancer https://t.co/BgjCnoieVq @JAMAO…
RT @MuinJKhoury: Using genetic risk scores, @paulpharoah and colleagues show cost-effectiveness analysis of risk-stratified screening for b…
RT @MuinJKhoury: Using genetic risk scores, @paulpharoah and colleagues show cost-effectiveness analysis of risk-stratified screening for b…
RT @dipi1_con: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified #Screening for #BreastCancer https://t.co/BgjCnoieVq @JAMAO…
Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified #Screening for #BreastCancer https://t.co/BgjCnoieVq @JAMAOnc #FOAMed #ECM https://t.co/pMy8uFvt9B
RT @MuinJKhoury: Using genetic risk scores, @paulpharoah and colleagues show cost-effectiveness analysis of risk-stratified screening for b…
RT @MuinJKhoury: Using genetic risk scores, @paulpharoah and colleagues show cost-effectiveness analysis of risk-stratified screening for b…
RT @MuinJKhoury: Using genetic risk scores, @paulpharoah and colleagues show cost-effectiveness analysis of risk-stratified screening for b…
RT @MuinJKhoury: Using genetic risk scores, @paulpharoah and colleagues show cost-effectiveness analysis of risk-stratified screening for b…
Using genetic risk scores, @paulpharoah and colleagues show cost-effectiveness analysis of risk-stratified screening for breast cancer. Promising results but @mclarkeroberts discusses implementation challenges. Via @JAMAOnc https://t.co/qMVSYxr5Oy & ht
RT @ChirSenologica: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified #Screening for #BreastCancer https://t.co/14Fg0rJs4t @…
Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified #Screening for #BreastCancer https://t.co/14Fg0rJs4t @JAMAOnc #FOAMed #ECM https://t.co/pOQbNx3JGk
RT @EricTopol: Why we should do mammography on the basis of risk, not on a mass, routine screening basis: less harm, less cost https://t.co…
RT @MuinJKhoury: A new @JAMAOnc paper explores the cost-effectiveness and benefit-to-harm ratio of genetic risk-stratified screening for br…
RT @GENES_PK: Since @KyrMichailidou et al. published the last big genome-wide association study of breast cancer last October, @Norapashaya…
RT @paulpharoah: Nice thread about all the work going on in the PRS space in breast cancer. The science continues to advance and many, man…
RT @GENES_PK: Since @KyrMichailidou et al. published the last big genome-wide association study of breast cancer last October, @Norapashaya…
Nice thread about all the work going on in the PRS space in breast cancer. The science continues to advance and many, many collaborators contribute.
RT @GENES_PK: Since @KyrMichailidou et al. published the last big genome-wide association study of breast cancer last October, @Norapashaya…
Since @KyrMichailidou et al. published the last big genome-wide association study of breast cancer last October, @Norapashayan and @paulpharoah published a nice paper on the cost-effectiveness of polygenic-stratified risk screening (in the UK). https://t.c
RT @Vilavaite: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model @JAMAOnc #br…
RT @Vilavaite: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model @JAMAOnc #br…
RT @Vilavaite: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model @JAMAOnc #br…
RT @Vilavaite: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model @JAMAOnc #br…
Cada vez hay mas sobre diagnostico de cáncer mama, haciendo mas daño que bien.
RT @Vilavaite: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model @JAMAOnc #br…
RT @EricTopol: Why we should do mammography on the basis of risk, not on a mass, routine screening basis: less harm, less cost https://t.co…
RT @MuinJKhoury: A new @JAMAOnc paper explores the cost-effectiveness and benefit-to-harm ratio of genetic risk-stratified screening for br…
RT @MyaLRoberson: I'm excited about the possibility of being more thoughtful in who we screen for #breastcancer and when, but I am terrifie…
RT @Vilavaite: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model @JAMAOnc #br…
Similar issues with prostate cancer screening.
RT @Vilavaite: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model @JAMAOnc #br…
RT @MyaLRoberson: I'm excited about the possibility of being more thoughtful in who we screen for #breastcancer and when, but I am terrifie…
RT @MyaLRoberson: I'm excited about the possibility of being more thoughtful in who we screen for #breastcancer and when, but I am terrifie…
RT @Vilavaite: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model @JAMAOnc #br…
RT @MyaLRoberson: I'm excited about the possibility of being more thoughtful in who we screen for #breastcancer and when, but I am terrifie…
I'm excited about the possibility of being more thoughtful in who we screen for #breastcancer and when, but I am terrified about the fact that most of the populations from which we derive our risk estimates are pretty uniformly White #healthequity https:
RT @RMilesMD: Cost-effectiveness & Benefit-to-Harm Ratio of Risk-Stratified Screening for #BreastCancer: A Life-Table Model @Norapashayan e…
RT @NHFTNHSLibrary: #Costeffectiveness and Benefit-to-Harm Ratio of Risk-Stratified #Screening for #breastcancer https://t.co/JvGMdFtThj #R…
RT @gotoPER: This week in @JAMAOnc: Not offering #breastcancer screening to low risk women could improve the cost-effectiveness, reduce ove…
RT @RMilesMD: Cost-effectiveness & Benefit-to-Harm Ratio of Risk-Stratified Screening for #BreastCancer: A Life-Table Model @Norapashayan e…
RT @drsebahattin: Meme kanseri, bir kadının yaşam süresince ( ki ortalama 70 yıl) %12,5 olasılık ile gözlenebilir (tabii abd verileri). Mam…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
Meme kanseri, bir kadının yaşam süresince ( ki ortalama 70 yıl) %12,5 olasılık ile gözlenebilir (tabii abd verileri). Mamografi ile tarama yaşı abd de bile 50 ve üzeri için tartışmalı iken bizde bazıları 40 yaşa indiriyor! Niye acaba? Paramız mı çok? http
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…
RT @EnferEvidente: El cribado de Cáncer de mama sólo es beneficioso y coste efectivo para mujeres en alto riesgo https://t.co/CKhdcsqI4n >N…